Scancell (LON:SCLP) Announces Quarterly Earnings Results

Scancell (LON:SCLP) announced its earnings results on Friday. The company reported GBX (1.73) EPS for the quarter, Digital Look Earnings reports. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%.

Scancell Stock Performance

Shares of LON:SCLP opened at GBX 9.36 on Friday. The company has a debt-to-equity ratio of -193.29, a current ratio of 0.56 and a quick ratio of 13.01. Scancell has a 1 year low of GBX 9.10 and a 1 year high of GBX 29.50. The firm has a market capitalization of £127.01 million, a PE ratio of -17.02 and a beta of 0.69. The business’s 50 day moving average price is GBX 9.68 and its 200-day moving average price is GBX 13.98.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.